Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Please indicate which comment is of concern and why. Your comments will be sent to our moderator for review.

Report comment to moderator

MandatoryRequired fields.


The true impact of the UK’s hormone replacement therapy shortages


FemSeven is marketed by Theramex, not Tevi (sic). Teva sold its woman's health portfolio to Theramex. I still don't understand why the Pharmaceutical Journal is not looking into the reasons for the shortages. Reporting what's happening is important to a certain extent, not after almost 2 years of shortages!

Posted date

6 MAR 2020

Posted time



Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.